| Drug Name |
Entrectinib |
| Drug ID |
BADD_D02553 |
| Description |
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929] |
| Indications and Usage |
Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults.[L8081] Entrectinib is also indicated in adults and children over 12 years old for the treatment of NTRK gene fusion-positive solid tumors which have metastasized or for which surgical resection is likely to result in severe morbidity and for which has progressed on previous therapies or for which no comparable alternative therapies are available. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EX14 |
| DrugBank ID |
DB11986
|
| KEGG ID |
D10926
|
| MeSH ID |
C000607349
|
| PubChem ID |
25141092
|
| TTD Drug ID |
D0O0LS
|
| NDC Product Code |
11014-0563; 50242-094; 11014-0551; 11014-0562; 50242-091; 11014-0550 |
| UNII |
L5ORF0AN1I
|
| Synonyms |
entrectinib | N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide | Rozlytrek | RXDX-101 | NMS-E628 |
